Dr. Gladysheva’s research is focused on the molecular and pathophysiologic mechanisms of cardiomyopathy, heart failure and concurrent complications in order to delay or prevent transition from cardiac dysfunction (cardiomyopathy) to symptomatic heart failure. Specifically, we are interested in proteases and hormones as potential diagnostic and therapeutic targets, and not pharmacological approaches (life-style choices) to modulate progression of cardiomyopathy and heart failure.